Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.650
+0.090 (5.77%)
Sep 18, 2025, 1:16 PM EDT - Market open
Acrivon Therapeutics Stock Forecast
ACRV's stock price has decreased by -78.55% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts that cover Acrivon Therapeutics stock have a consensus rating of "Buy" and an average price target of $17.75, which forecasts a 975.76% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $27.
Price Target: $17.75 (+975.76%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 14, 2025.
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +384.85% | Aug 14, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 16, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +445.45% | May 15, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 → $10 | Buy | Maintains | $18 → $10 | +506.06% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +1,051.52% | Mar 28, 2025 |
Financial Forecast
Revenue This Year
147.90K
Revenue Next Year
1.34M
from 147.90K
Increased by 805.34%
EPS This Year
-2.26
from -2.38
EPS Next Year
-2.18
from -2.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2M | 11.0M | |||
| Avg | 147,900 | 1.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 7,354.4% | |||
| Avg | - | 805.3% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.83 | -0.63 | |||
| Avg | -2.26 | -2.18 | |||
| Low | -2.75 | -3.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.